Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations

NCT04762602 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT04762602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04762602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Locally Advanced or Metastatic Solid Tumors With IDH Mutations
Lead sponsor
Hutchmed
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2021
Completion date
February 27, 2025
Enrollment
42 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

isocitrate dehydrogenase gene mutation